JP2010539095A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539095A5
JP2010539095A5 JP2010524243A JP2010524243A JP2010539095A5 JP 2010539095 A5 JP2010539095 A5 JP 2010539095A5 JP 2010524243 A JP2010524243 A JP 2010524243A JP 2010524243 A JP2010524243 A JP 2010524243A JP 2010539095 A5 JP2010539095 A5 JP 2010539095A5
Authority
JP
Japan
Prior art keywords
substituted
aryl
cycloalkyl
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524243A
Other languages
English (en)
Japanese (ja)
Other versions
JP5688840B2 (ja
JP2010539095A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/075848 external-priority patent/WO2009036059A2/en
Publication of JP2010539095A publication Critical patent/JP2010539095A/ja
Publication of JP2010539095A5 publication Critical patent/JP2010539095A5/ja
Application granted granted Critical
Publication of JP5688840B2 publication Critical patent/JP5688840B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524243A 2007-09-10 2008-09-10 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤 Expired - Fee Related JP5688840B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US60/971,144 2007-09-10
US1337207P 2007-12-13 2007-12-13
US61/013,372 2007-12-13
PCT/US2008/075848 WO2009036059A2 (en) 2007-09-10 2008-09-10 Novel stat3 pathway inhibitors and cancer stem cell inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014232396A Division JP6106149B2 (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014232397A Division JP2015034179A (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤

Publications (3)

Publication Number Publication Date
JP2010539095A JP2010539095A (ja) 2010-12-16
JP2010539095A5 true JP2010539095A5 (https=) 2012-09-27
JP5688840B2 JP5688840B2 (ja) 2015-03-25

Family

ID=40452461

Family Applications (16)

Application Number Title Priority Date Filing Date
JP2010524243A Expired - Fee Related JP5688840B2 (ja) 2007-09-10 2008-09-10 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2010524251A Expired - Fee Related JP5872160B2 (ja) 2007-09-10 2008-09-10 癌治療のための新規の組成物および方法
JP2010524249A Expired - Fee Related JP5701603B2 (ja) 2007-09-10 2008-09-10 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014177915A Expired - Fee Related JP5938072B2 (ja) 2007-09-10 2014-09-02 癌治療のための新規の組成物および方法
JP2014177908A Expired - Fee Related JP5925849B2 (ja) 2007-09-10 2014-09-02 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014232397A Withdrawn JP2015034179A (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014232396A Expired - Fee Related JP6106149B2 (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2015230291A Expired - Fee Related JP6358659B2 (ja) 2007-09-10 2015-11-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016004076A Expired - Fee Related JP6347795B2 (ja) 2007-09-10 2016-01-13 癌治療のための新規の組成物および方法
JP2016016973A Expired - Fee Related JP6346628B2 (ja) 2007-09-10 2016-02-01 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016097607A Withdrawn JP2016147906A (ja) 2007-09-10 2016-05-16 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2017242778A Withdrawn JP2018076349A (ja) 2007-09-10 2017-12-19 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2018102234A Withdrawn JP2018131464A (ja) 2007-09-10 2018-05-29 癌治療のための新規の組成物および方法
JP2019029436A Pending JP2019073560A (ja) 2007-09-10 2019-02-21 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2020085065A Pending JP2020117547A (ja) 2007-09-10 2020-05-14 癌治療のための新規の組成物および方法
JP2020091326A Pending JP2020143135A (ja) 2007-09-10 2020-05-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ

Family Applications After (15)

Application Number Title Priority Date Filing Date
JP2010524251A Expired - Fee Related JP5872160B2 (ja) 2007-09-10 2008-09-10 癌治療のための新規の組成物および方法
JP2010524249A Expired - Fee Related JP5701603B2 (ja) 2007-09-10 2008-09-10 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014177915A Expired - Fee Related JP5938072B2 (ja) 2007-09-10 2014-09-02 癌治療のための新規の組成物および方法
JP2014177908A Expired - Fee Related JP5925849B2 (ja) 2007-09-10 2014-09-02 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014232397A Withdrawn JP2015034179A (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014232396A Expired - Fee Related JP6106149B2 (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2015230291A Expired - Fee Related JP6358659B2 (ja) 2007-09-10 2015-11-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016004076A Expired - Fee Related JP6347795B2 (ja) 2007-09-10 2016-01-13 癌治療のための新規の組成物および方法
JP2016016973A Expired - Fee Related JP6346628B2 (ja) 2007-09-10 2016-02-01 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016097607A Withdrawn JP2016147906A (ja) 2007-09-10 2016-05-16 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2017242778A Withdrawn JP2018076349A (ja) 2007-09-10 2017-12-19 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2018102234A Withdrawn JP2018131464A (ja) 2007-09-10 2018-05-29 癌治療のための新規の組成物および方法
JP2019029436A Pending JP2019073560A (ja) 2007-09-10 2019-02-21 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2020085065A Pending JP2020117547A (ja) 2007-09-10 2020-05-14 癌治療のための新規の組成物および方法
JP2020091326A Pending JP2020143135A (ja) 2007-09-10 2020-05-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ

Country Status (14)

Country Link
US (12) US8877803B2 (https=)
EP (6) EP3050566B1 (https=)
JP (16) JP5688840B2 (https=)
CN (6) CN105963289B (https=)
CA (4) CA2911990C (https=)
CY (3) CY1117604T1 (https=)
DK (4) DK2200431T3 (https=)
ES (3) ES2583010T3 (https=)
HR (3) HRP20160430T1 (https=)
HU (3) HUE029111T2 (https=)
PL (4) PL2194987T3 (https=)
PT (2) PT2194987T (https=)
SI (3) SI2200431T1 (https=)
WO (3) WO2009036101A1 (https=)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
US20130129675A1 (en) * 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
KR101778320B1 (ko) * 2009-12-28 2017-09-13 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 1,3,4-옥사디아졸-2-카르복사미드 화합물
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
PT2547205T (pt) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Novos métodos para atingir células estaminais cancerígenas
RU2571661C2 (ru) * 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
CN103153975B (zh) * 2010-08-24 2016-01-20 杭州益尔生物科技有限公司 用于疾病治疗的新型萘醌
JP5674798B2 (ja) * 2010-09-16 2015-02-25 国立大学法人大阪大学 自己免疫疾患、炎症性疾患、アレルギー性疾患、臓器移植に伴う症状の治療薬および予防薬
WO2012071321A1 (en) * 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
CN103260647A (zh) * 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 用于治疗心脏病的egfr拮抗剂
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
EP2717870B1 (en) * 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
SG10201601917XA (en) * 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
CA2855368A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013120229A1 (en) * 2012-02-17 2013-08-22 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN106421795A (zh) * 2012-10-08 2017-02-22 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
RU2016128396A (ru) * 2014-01-27 2018-03-02 Бостон Биомедикал, Инк. Новые способы лечения рака
US10017488B2 (en) * 2014-02-07 2018-07-10 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof
WO2015120436A2 (en) 2014-02-10 2015-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 phosphorylation during graft-versus-host disease
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) * 2014-05-09 2015-11-12 The Brigham And Women's Hospital, Inc. Treatment of igg-immune complex-mediated organ damage
US10005752B2 (en) 2014-06-09 2018-06-26 Kyoto Pharmaceutical Industries, Ltd. Anticancer agent
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
US10906914B2 (en) 2015-01-08 2021-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furoquinolinediones as inhibitors of TDP2
US10183925B2 (en) 2015-03-27 2019-01-22 Boston Biomedical, Inc. Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
US20180085341A1 (en) * 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
TW201709905A (zh) * 2015-04-17 2017-03-16 波士頓生醫公司 治療癌症之方法
BR112017022269A2 (pt) * 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
CN107683137A (zh) * 2015-04-27 2018-02-09 波士顿生物医药有限公司 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法
EP3415149A1 (en) * 2015-05-14 2018-12-19 NuCana plc Cancer treatments
EP3294299A1 (en) * 2015-05-15 2018-03-21 Novartis AG Methods for treating egfr mutant cancers
MX2017015618A (es) * 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
WO2017013865A1 (ja) * 2015-07-17 2017-01-26 大日本住友製薬株式会社 ２－アセチル－４Ｈ，９Ｈ－ナフト［２，３－ｂ］フラン－４，９－ジオンの製造方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
AU2017205478A1 (en) * 2016-01-07 2018-06-28 Swadesh K. Das A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
WO2017151625A1 (en) * 2016-03-01 2017-09-08 Academia Sinica 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017164379A1 (ja) 2016-03-25 2017-09-28 大日本住友製薬株式会社 ２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2019519573A (ja) 2016-06-28 2019-07-11 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
US20190375723A1 (en) 2016-11-22 2019-12-12 Boston Biomedical, Inc. New Naphtho[2,3-B]Furan Derivatives
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) * 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3045110A1 (en) * 2016-11-30 2018-06-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
CN113769097A (zh) * 2017-01-22 2021-12-10 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CA3066053A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
WO2019018207A1 (en) * 2017-07-20 2019-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College TARGETED OSMOTIC LYSE OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS
WO2019059344A1 (ja) 2017-09-22 2019-03-28 大日本住友製薬株式会社 化学活性化型水溶性プロドラッグ
EP3710050A4 (en) * 2017-11-16 2021-06-16 TyrNovo Ltd. COMBINATIONS OF IRS / STAT3 DOUBLE MODULATORS AND ANTI-PD-1 / PD-L1 AMBODIES FOR TREATMENT OF CANCER
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
EP3733840A4 (en) * 2017-12-28 2021-11-24 Kaneka Corporation INHIBITOR OF PLURIPOTENT STEM CELL AGGREGATION
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
EA202092206A1 (ru) * 2018-03-20 2020-12-15 Сумитомо Дайниппон Фарма Ко., Лтд. Производные дигидрохромена
US11826315B2 (en) * 2018-04-19 2023-11-28 Tvardi Therapeutics STAT3 inhibitors
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
JPWO2020059705A1 (ja) * 2018-09-18 2021-08-30 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020207344A1 (zh) * 2019-04-09 2020-10-15 健艾仕生物医药有限公司 匹莫齐特和甲氨蝶呤的药物组合及其应用
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
JPWO2020251015A1 (https=) * 2019-06-14 2020-12-17
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
EP4054579A1 (en) * 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
JP7674354B2 (ja) * 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
WO2021230956A1 (en) * 2020-05-11 2021-11-18 Purdue Research Foundation Scaled-up synthesis of lomustine under continuous flow conditions
WO2022022524A1 (en) * 2020-07-27 2022-02-03 Huazhong University Of Science & Technology Prevention and/or treatment of a disease associated with stat3
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) * 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
EP0466094B1 (en) * 1990-07-10 1999-03-24 Canon Kabushiki Kaisha Electrophotographic photosensitive member
TW252136B (https=) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
EP1985285A3 (en) * 1999-04-01 2009-08-12 Hana Biosciences, Inc. Compositions and methods for treating lymphoma
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
KR100466730B1 (ko) 1999-08-02 2005-01-24 에프. 호프만-라 로슈 아게 신규한 선택적 레티노이드 작용물질
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
WO2002078617A2 (en) * 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
AU2002351177A1 (en) 2001-11-29 2003-06-10 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
JP2005526084A (ja) * 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
AU2002336473A1 (en) 2002-09-10 2004-04-30 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
EP1551392A4 (en) * 2002-09-17 2006-09-20 Arqule Inc NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
AU2004296828B2 (en) 2003-12-02 2011-07-07 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
PT1701941E (pt) * 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
CA2563305A1 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
JP2008505112A (ja) * 2004-07-02 2008-02-21 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
AU2005304952B2 (en) * 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
RU2007123675A (ru) * 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
CA2599393A1 (en) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of stat3 and the uses thereof
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006126505A1 (ja) 2005-05-26 2006-11-30 The University Of Tokyo Stat機能阻害剤およびその応用
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
NZ567266A (en) 2005-10-13 2010-09-30 Orchid Res Lab Ltd Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol)
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
BRPI0620624A2 (pt) * 2005-12-24 2011-11-16 Biotica Tech Ltd análogo de 21-deóximacbecina ou um sal farmaceuticamente aceitável do mesmo, método para a produção do mesmo, composição farmacêutica, cepas hospedeira e engenheirada, e, uso das mesmas
CA2635209A1 (en) * 2006-01-12 2007-08-02 Merck & Co., Inc. Fluorinated arylamide derivatives
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007100640A2 (en) 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
AU2007218966A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
BRPI0709916B8 (pt) * 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
PT2547205T (pt) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Novos métodos para atingir células estaminais cancerígenas
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
TW201709905A (zh) 2015-04-17 2017-03-16 波士頓生醫公司 治療癌症之方法
BR112017022269A2 (pt) 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
CN107683137A (zh) 2015-04-27 2018-02-09 波士顿生物医药有限公司 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法
MX2017015618A (es) 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2010539095A5 (https=)
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
CN104736155B (zh) 双环化合物作为激酶的抑制剂
JP2019535720A5 (https=)
JP2019529500A5 (https=)
EP2563761A1 (en) Activators of human pyruvate kinase
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
JP2018503648A (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
JP2008535902A5 (https=)
KR20190086442A (ko) 피리딘 화합물
KR20160115991A (ko) Midh1 억제제로서의 벤즈이미다졸-2-아민
HK1221717A1 (zh) 取代的苄基吡唑
KR20180105700A (ko) 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용
JP2017529353A (ja) Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
WO2019060611A1 (en) CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES
EP3710456A1 (en) Macrocyclic indole derivatives
WO2019096922A1 (en) Substituted macrocyclic indole derivatives
JP2014520108A5 (https=)
JP2015536997A5 (https=)
WO2016091845A1 (en) Novel aryl-cyanoguanidine compounds
JP2015522607A (ja) プロテインキナーゼに対する阻害活性を有するイソキノリン−５−カルボキサミド誘導体
KR20210053911A (ko) Ahr 조절제로서의 헤테로사이클릭 화합물
JP2018535235A (ja) １，３，４−チアジアゾール化合物およびがんの治療におけるその使用
JP2015502371A5 (https=)